Special Issue "Advances in Ricin Antitoxins: From Intoxication to Diagnosis and Treatment"
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 10204
Interests: biothreat agents; intoxication; medical countermeasures; detection and identification
Ricin is a potent (type 2) ribosome-inactivating protein toxin produced in the seeds of the castor bean plant Ricinus communis. Accidental and/or intentional exposure to the toxin can have serious consequences for the health and the survival of both humans and animals. This is a consequence of the potency of the toxin along with the prevalence of castor beans in the environment (i.e., increasing the likelihood of exposure). The identification of ricin intoxication in a clinical setting remains very challenging and is further complicated by a delayed onset of symptoms. Additionally, there is a current lack of licensed medical interventions, with supportive therapy representing the main clinical option. Nevertheless, a number of new small molecule inhibitors rationally developed using structural-functional analysis and that affect the intracellular trafficking of the toxin are alternative approaches to the more traditional antibody-based molecules which have also recently demonstrated promise as candidate countermeasures for the treatment of ricin exposure in animal models.
This Special Issue will focus on the steps being taken to develop emerging candidate therapies for treating ricin exposure. In addition, research that will improve the following will also be considered:
- The efficacy of candidate therapies including formulation;
- Earlier diagnosis of exposure to the toxin;
- The understanding of the toxin’s direct mechanism of action or the process of intoxication that will aid the development of next-generation medical countermeasures.
Prof. Dr. Graeme C. Clark
Dr. Damien Chong
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Ricinus communis
- medical countermeasures